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Abstract
Rationale: Oral treprostinil improves exercise capacity in patients
with pulmonary arterial hypertension (PAH), but the effect on
clinical outcomes was unknown.
Objectives:To evaluate the effect of oral treprostinil comparedwith
placebo on time to first adjudicated clinical worsening event in
participants with PAH who recently began approved oral
monotherapy.
Methods: In this event-driven, double-blind study, we randomly
allocated 690 participants (1:1 ratio) with PAH to receive placebo or
oral treprostinil extended-release tablets three times daily. Eligible
participants were using approved oral monotherapy for over 30 days
before randomization and had a 6-minute-walk distance 150 m or
greater. The primary endpoint was the time to first adjudicated
clinical worsening event: death; hospitalization due to worsening
PAH; initiation of inhaled or parenteral prostacyclin therapy; disease
progression; or unsatisfactory long-term clinical response.
Measurements and Main Results: Clinical worsening occurred
in 26% of the oral treprostinil group compared with 36% of placebo
participants (hazard ratio, 0.74; 95% confidence interval, 0.56–0.97;
P= 0.028). Key measures of disease status, including functional class,
Borg dyspnea score, and N-terminal pro–brain natriuretic peptide,
all favored oral treprostinil treatment at Week 24 and beyond.
A noninvasive risk stratification analysis demonstrated that oral
treprostinil–assigned participants had a substantially higher
mortality risk at baseline but achieved a lower risk profile from
Study Weeks 12–60. The most common adverse events in the oral
treprostinil group were headache, diarrhea, flushing, nausea, and
vomiting.
Conclusions: In participants with PAH, addition of oral treprostinil
to approved oralmonotherapy reduced the risk of clinical worsening.
Clinical trial registered with www.clinicaltrials.gov (NCT01560624).
Keywords: pulmonary arterial hypertension; oral treprostinil;
clinical study; combination therapy; sequential therapy
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Pulmonary arterial hypertension (PAH) is a
rare, but progressive and often fatal,
pulmonary vascular disease. Treatment
options have expanded greatly in the past
20 years (1), and two event-driven studies
of sequential combination therapy have
established the durable benefit of the
endothelin receptor antagonist (ERA)
macitentan (2) and the prostacyclin
receptor agonist selexipag (3).
Epoprostenol, the endogenous agonist for
the prostacyclin receptor, is highly effective
in PAH, but it is short acting and requires
continuous intravenous infusion (4).
Selexipag was thus a significant addition to
treatment options as a long-acting and
orally available, selective prostacyclin IP
receptor agonist. Oral extended-release
treprostinil diolamine tablets improved
exercise capacity when dosed twice daily in
treatment-naive patients with PAH (5).
Oral treprostinil dosed three times daily
had a better pharmacokinetic profile,
allowed participants to achieve a higher
total daily dose, and substituted for
parenteral treprostinil in a cohort of
carefully selected participants with PAH
(6). Therefore, the FREEDOM-EV study
hypothesized that combination therapy
with oral treprostinil would reduce the risk
of clinical worsening events in patients who
had recently started oral monotherapy for
PAH. Preliminary results of this study have
been previously reported in the form of
conference abstracts (7–9).
Methods
Study Design
The FREEDOM-EV trial was a multicenter,
randomized, double-blind, placebo-
controlled, event-driven study. Investigators
from 152 centers across 23 countries
conducted the study between June 2012 and
June 2018. The steering committee, in
collaboration with the sponsor, designed the
study protocol (see the online supplement),
and the institutional review board at each
center approved the protocol. The sponsor
collected and analyzed the data according
to a prespecified statistical analysis plan. An
independent data monitoring committee
supervised the study, and all authors had
access to the source-verified data and attest
to the accuracy and completeness of this
report.
Selection of Participants
Participants were 18–75 years of age, met
the 2013 consensus definition of World
Health Organization (WHO) Group 1
pulmonary hypertension (10), and had a
6-minute-walk distance (6MWD) 150 m or
greater at the screening visit. Historical
right heart catheterization within 3 years
(or during the screening period) must have
demonstrated a mean pulmonary artery
pressure of 25 mm Hg or greater and a
pulmonary artery wedge pressure of
15 mm Hg or less. Based on the
AMBITION study (11), protocol
amendment 5 excluded participants who
had three or more of the following risk
factors for heart failure with preserved
ejection fraction: 1) body mass index of 30
kg/m2 or greater; 2) essential hypertension;
3) diabetes mellitus; or 4) clinically
significant coronary artery disease. The
initial protocol sought to enroll participants
soon after they began oral monotherapy
(between 30 and 90 d of beginning an
approved dose and schedule of sildenafil,
tadalafil, bosentan, ambrisentan,
macitentan, or riociguat). Subsequent
amendments expanded the monotherapy
treatment window to address slow
enrollment. The full set of protocol entry
criteria are provided in the online
supplement. All the participants provided
written informed consent.
Trial Procedures
Randomization (1:1) was stratified
by type of background therapy
(i.e., phosphodiesterase type 5 [PDE5]
inhibitor or soluble guanylate cyclase [SGC]
stimulator vs. ERA) and by baseline 6MWD
(breakpoint <350 m). Participants initially
took oral treprostinil or matching placebo
0.125 mg three times daily (spaced carefully
every 6–8 h with food). The protocol
allowed daily up-titration in 0.125 mg
increments for the first 4 weeks and 0.25-
mg daily titration thereafter to a maximum
dose of 12 mg three times daily. We
instructed investigators to increase doses
steadily and to assess the need for dose
adjustment during weekly telephone calls,
attempting to balance the expected adverse
drug effects with the apparent clinical
benefits (i.e., a reduction in the signs and
symptoms of PAH).
Outcome Measures
The primary endpoint was the time to first
adjudicated clinical worsening event, which
was defined as death from any cause,
hospitalization for worsening PAH, disease
progression, initiation of inhaled or infused
prostacyclin therapy, or unsatisfactory
Author Contributions: R.J.W. is the Principal Investigator of the study and contributed substantially to the protocol, beginning with amendment 2; actively
recruited and treated participants in the study; served as the academic lead for analysis and interpretation of the data; and wrote the initial manuscript draft.
C.J.-S., G.M.B.M., T.P., P.S., K.Y.W., E.G., S.H., Z.Y., Z.G., W.L.J.Y., S.Z., and A.K. are investigators in the study and actively recruited and treated
participants in the study and made revisions to the manuscript. V.F.T. shared leadership responsibility with R.J.W. in the analysis and interpretation of data and
early revisions of the manuscript. R.G. served as medical monitor for the study and provided critical input to data analysis and manuscript revision. C.Q.D.
managed the study database, performed and directed all the statistical analyses per the statistical analysis plan, helped with interpretation of the statistics and
their inclusion in the manuscript, supported additional analyses requested by the other authors, and revised the manuscript throughout its development. All
authors approved the decision to submit the manuscript for publication.
At a Glance Commentary
Scientific Knowledge on the
Subject: Oral treprostinil improved
exercise capacity in treatment-naive
patients with pulmonary arterial
hypertension (PAH) and substituted
for parenteral treprostinil in a carefully
selected group of participants, but the
effect on clinical outcomes was
unknown.
What This Study Adds to the Field:
This multicenter, randomized, double-
blind placebo-controlled trial
demonstrates that initiation of oral
treprostinil reduces the risk of clinical
worsening events in participants who
had recently (median, 5.4 mo) started
oral monotherapy for PAH. Secondary
endpoints, including N-terminal
pro–brain natriuretic peptide and a
multifaceted noninvasive risk
assessment, improved in oral
treprostinil–assigned participants
beginning at Week 12 and continuing
through Week 60.
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long-term clinical response (definitions
provided in the online supplement). Three
disease experts (not otherwise participating
in the study) formed a blinded, independent
clinical event committee, which adjudicated
all clinical worsening events using a
narrative that was stripped of information
about adverse events or dosing that might
cue them to treatment assignment.
Investigator teams met participants at
Weeks 4, 8, and 12, and then at 12-week
intervals throughout the study to conduct
efficacy assessments, including 6MWD,
Borg dyspnea score, plasma N-terminal
pro–brain natriuretic peptide (NT-
proBNP) levels, and WHO functional class.
Before the final statistical analysis plan was
submitted to the U.S. Food and Drug
Administration and before unblinding,
we planned a risk analysis using three
noninvasive variables as previously proposed
(12) and validated (13) (e.g., 6MWD, NT-
proBNP, and WHO functional class). Safety
assessments included evaluation of adverse
events and clinical laboratory parameters.
Beginning in 2015, with protocol amendment
6, we collected vital status by phone every 6
months for those who discontinued the study;
survival analysis was prespecified in the
statistical plan submitted to the Food and
Drug Administration.
Statistical Analysis
The final power calculation estimated that
205 adjudicated events would provide at
least 90% power (type I error rate, 0.05; two
tailed) to detect a difference in the time to
adjudicated clinical worsening event
between treatment groups, assuming
exponential distributions and an underlying
hazard ratio of 0.62. We assumed a placebo
event rate of 23% atMonth 12 and accrual of
subjects over 3 years with 10% attrition.
These assumptions indicated a sufficient
sample size would be 610–850 participants;
we closed enrollment at 690 participants
when we approached the required 205
events. The primary efficacy endpoint had
been tested at an interim analysis when
approximately 75% of the total adjudicated
events had occurred with a prespecified
decision to stop if the interim type I error
was less than 0.02; this required that the
final analysis have an a of less than 0.044
for an overall type I error rate at 0.05. The
main analyses for the primary and
secondary endpoints were performed in the
entire population. For the primary efficacy
analysis of time to adjudicated clinical
worsening event, data were summarized by
treatment group using product-limit
estimates calculated by the Kaplan-Meier
method. The log-rank test adjusted for the
type of background PAH therapy (PDE5
inhibitor or SGC stimulator vs. ERA), and
the baseline 6MWD (breakpoint <350 m)
was used to calculate significance for
treatment differences in the intention-to-
treat population. The risk of clinical
worsening was also compared between
treatment groups using a Cox proportional
hazards regression model to estimate a
hazard ratio and its 95% confidence interval
(CI), also adjusting for background PAH
therapy and baseline 6MWD. All safety
analyses were also performed in the entire
population.
Screened
n=837
Screen Failure
n=147
Randomized and
Received Study Drug
n=690
Oral Treprostinil
n=346
•  Progressive Disease (n=10)*
•  Adverse Event (n=65)†
•  Withdrawal by Subject (n=19)
•  Protocol Violation (n=4)
•  Lost to Follow-up (n=5)
•  Other (n=4)
Early Discontinuation from
Treatment
n=107
Clinical Worsening
Event Including Death
(Reported by
Investigators)
n=91
Clinical Worsening
Event Including Death
(Reported by
Investigators)‡
n=133
Completed the Study
Without Clinical
Worsening or Early
Discontinuation
n=148
Completed the Study
Without Clinical
Worsening or Early
Discontinuation
n=155
•  Other (n=5)
•  Progressive Disease (n=4)*
•  Adverse Event (n=14)†
•  Withdrawal by Subject (n=29)
•  Protocol Violation (n=4)
Early Discontinuation from
Treatment
n=56
Placebo
n=344
Figure 1. Patient disposition. *Includes one subject in the oral treprostinil group and one subject in
the placebo group who experienced clinical worsening events due to urgent hospitalization for
treatment of worsening pulmonary arterial hypertension. †Includes one subject in the oral treprostinil
group and one subject in the placebo group who experienced clinical worsening events due to fatal
serious adverse events, and one subject in the oral treprostinil group who discontinued treatment due
to an adverse event, but remained in the study until death (which did not qualify as a clinical
worsening event). ‡Includes one subject in the placebo group who died after discontinuation of study
treatment due to clinical worsening.
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Results
Participants
We randomly allocated 690 participants
to oral treprostinil (346 participants) or
placebo (344 participants) treatment groups
(Figure 1). Table 1 shows the demographic
and clinical characteristics of participants;
individual characteristics were largely
balanced at baseline. We enrolled
participants after beginning initial
monotherapy (median time, 5.4 mo).
Participants were predominantly female;
63% had WHO functional class II
symptoms, and 72% were taking a PDE5
inhibitor or SGC stimulator. Median dose
of oral treprostinil achieved at Week 24
was 3.56 mg three times daily, which
corresponds to titration by approximately
0.125 mg once weekly (288 oral treprostinil
participants; see Figure E1 in the online
supplement). Median dose of placebo at
Week 24 was 6 mg three times daily (289
placebo participants).
Primary Efficacy Endpoint
Overall, 90 (26%) participants in the
oral treprostinil group experienced an
adjudicated clinical worsening event
compared with 124 (36%) placebo
participants. Kaplan-Meier estimates of the
time to adjudicated clinical worsening event
suggested group separation before Week
24 (Figure 2A, log-rank test, P= 0.039);
the hazard ratio adjusted for background
therapy and baseline 6MWD as a
continuous variable was 0.74 (95% CI,
0.56–0.97; P= 0.028). When adjusted for
baseline 6MWD as a categorical variable
(breakpoint <350 m), the hazard ratio was
0.75 (95% CI, 0.57–0.99; P= 0.040). The
median time to clinical worsening was 46
weeks with oral treprostinil and 37 weeks
with placebo. The treatment-attributable
difference in clinical worsening was driven
by a reduced incidence of disease
progression in the oral treprostinil group
(hazard ratio, 0.39; 95% CI, 0.23–0.66;
P, 0.001). Deaths and hospitalizations
were balanced. Subgroup analyses of the
primary endpoint, based on age, sex,
baseline 6MWD, WHO functional class,
PAH etiology, geographic region, and
background oral PAH therapy did not show
any significant interactions between
subgroup and treatment (see Figure E2).
Individual components of the
demographics suggested balanced
participant characteristics at baseline;
however, a prespecified (before unblinding),
noninvasive risk stratification (12) indicated
that the oral treprostinil–assigned group
had a higher mortality risk at baseline.
Placebo-assigned participants had more
low-risk criteria (e.g., WHO functional
class I or II symptoms, 6MWD .440 m,
and NT-proBNP ,300 pg/ml) compared
with the oral treprostinil group (Fisher’s
exact test, P= 0.002, Table 1). We thus
conducted a post hoc analysis accounting
for baseline risk profile (number of low-risk
factors, 0–3); the hazard ratio for a clinical
worsening event dropped further to 0.61
(95% CI, 0.46–0.81; P, 0.001). Arbitrarily
classifying those with two to three low-risk
Table 1. Baseline Characteristics*
Characteristic
Oral Treprostinil
(n=346)
Placebo
(n= 344)
Overall
(n=690)
Age, yr 45.6615.7 44.8615.4 45.2615.5
Sex, F, n (%) 275 (79.5) 269 (78.2) 544 (78.8)
Race, n (%)
White 187 (54.0) 173 (50.3) 360 (52.2)
Black or African American 8 (2.3) 13 (3.8) 21 (3.0)
Asian 150 (43.4) 156 (45.3) 306 (44.3)
Unknown 1 (0.3) 2 (0.6) 3 (0.4)
Region, n (%)
North America 39 (11.3) 54 (15.7) 93 (13.5)
Asia-Pacific 162 (46.8) 160 (46.5) 322 (46.7)
Europe 55 (15.9) 44 (12.8) 99 (14.3)
Latin America 90 (26.0) 86 (25.0) 176 (25.5)
Median time since diagnosis
(IQR), mo
6.2 (2.4–13.3) 6.5 (2.28–13.2) 6.4 (2.3–13.3)
Etiology of PAH, n (%)
Idiopathic or heritable PAH 219 (63.3) 216 (62.8) 435 (63.0)
Connective tissue disease 94 (27.2) 84 (24.4) 178 (25.8)
HIV infection 2 (0.6) 7 (2.0) 9 (1.3)
Congenital heart defect 20 (5.8) 27 (7.8) 47 (6.8)
Other 11 (3.2) 10 (2.9) 21 (3.0)
6MWD, n (%)
<350 m 95 (27.5) 93 (27.0) 188 (27.2)
.350 m 251 (72.5) 251 (73.0) 502 (72.8)
6MWD, m 392.9692.5 398.56100.0 395.76 96.3
WHO functional class at baseline,
n (%)
I 9 (2.6) 13 (3.8) 22 (3.2)
II 205 (59.2) 228 (66.3) 433 (62.8)
III 131 (37.9) 103 (29.9) 234 (33.9)
IV 1 (0.3) 0 1 (0.1)
Background PAH therapy at
baseline, n (%)
PDE5 inhibitor or SGC stimulator
alone
248 (71.7) 246 (71.5) 494 (71.6)
ERA alone 98 (28.3) 98 (28.5) 196 (28.4)
Median time on background PAH
therapy at baseline (IQR), mo
5.3 (2.3–10.7) 5.5 (2.4–10.6) 5.4 (2.4–10.7)
Risk stratification by number of
low-risk criteria met†‡, n (%)
—
0 85 (25.2) 59 (17.7)
1 112 (33.2) 110 (32.9)
2 102 (30.3) 94 (28.1)
3 38 (11.3) 71 (21.3)
Definition of abbreviations: 6MWD=6-minute-walk distance; ERA=endothelin receptor antagonist;
IQR= interquartile range; PAH=pulmonary arterial hypertension; PDE5=phosphodiesterase type 5;
SGC=soluble guanylate cyclase; WHO=World Health Organization.
*Plus/minus values are means6SD. Testing of baseline characteristics showed that there were no
significant between-group differences at baseline, except regarding risk stratification by number of
low-risk criteria.
†Low-risk criteria defined as WHO functional class I or II, 6MWD greater than 440 m, and/or
N-terminal pro–brain natriuretic peptide less than 300 pg/ml. Low-risk criteria met were only counted
for subjects with all three measures available; n=337 oral treprostinil, n=334 placebo.
‡
P=0.002; P value was obtained from Fisher’s exact test.
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factors as “lower risk” and those with zero
to one low-risk factors as “higher risk”
resulted in two groups of similar size
(n= 366 vs. 305). We re-estimated Kaplan-
Meier time-to-event curves for these two
groups, finding that oral treprostinil
protected higher-risk participants from
clinical worsening events (log-rank,
P= 0.006; Figure 2B).
Secondary and Exploratory Efficacy
Endpoints
Plasma NT-proBNP levels decreased in the
oral treprostinil group beginning atWeek 12
(Figure 3). WHO functional class improved
significantly for participants in the oral
treprostinil group at all visits from Week 12
to Week 48 when compared with the
placebo group (Figure 4A). Improvement
was observed as both a higher proportion
of favorable (“improved”) and a lower
proportion of worsening (“deteriorated”)
categorical change from baseline. At Week
24, oral treprostinil participants increased
their 6MWD 16 m (least squares mean)
compared with 8 m in the placebo group
(mixed-model repeated measurement
[MMRM] estimate of treatment effect, 8 m
[95% CI, 22 to 18; P= 0.12], Table 2). By
Week 36, treatment difference in 6MWD
was clear (MMRM=13 m [95% CI, 1–25];
P= 0.04), and this increased further at
Week 48 (MMRM=22 m [95% CI, 8–35;
P= 0.002]; see Figure E3). Hodges-
Lehmann estimate of treatment effect
yielded similar results (see Figure E4).
Although the change in 6MWD was not
statistically different between the treatment
groups at Weeks 12 or 24, categorical
changes in Borg dyspnea score measured at
the end of each walk test favored oral
treprostinil at assessments from Week 12 to
Week 48 (Figure 4B). Similarly, the
combined 6MWD/Borg dyspnea score
ranking, a statistical method for analyzing
changes in walk distance and associated
changes in Borg dyspnea score, favored the
oral treprostinil treatment group at Week
24 (see Figure E5).
We hypothesized a priori (before
unblinding) that oral treprostinil applied as
sequential combination therapy would
improve risk assessments at follow-up. We
obtained the necessary variables to define
the recently proposed, noninvasive risk
assessment at Weeks 12, 24, 36, and 60. At
each assessment, the Fisher’s exact analysis
of those having categorical change was
highly significant (P, 0.002), with more
oral treprostinil participants having an
improved risk profile and fewer having a
deteriorated risk profile (Figure 4C). A post
hoc analysis using the Reveal 2.0 risk score
(14) yielded a similar result beginning at
Week 12 (see Table E1).
The initial data collection plan stopped
following participants 30 days after
discontinuing randomized treatment unless
they consented to participate in an open-
label follow-up study. An amended protocol
issued in 2015 collected vital status every 6
months for consenting participants until
final study closure in October 2018. As of
October 2018, 38 (11%) participants initially
assigned to oral treprostinil were confirmed
dead compared with 60 (17.4%) in the
placebo group (hazard ratio, 0.63; 95% CI,
0.42–0.95; P= 0.026; Table 2). Because we
did not begin collecting vital status until
some participants had exited the study
(and some investigative sites had closed),
survival could not be confirmed for 74
(11%) participants. A sensitivity analysis
assuming the observed mortality rate in
those with unknown vital status still
favored oral treprostinil (see Tables E2
and E3).
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Hazard ratio 0.64 (95% CI, 0.46–0.88), P=0.006†
Hazard ratio 0.64 (95% CI, 0.36–1.13), P=0.126†
Oral treprostinil / higher risk (0, 1)
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B
Figure 2. Kaplan-Meier plots of primary endpoint and primary endpoint by baseline risk
stratification. (A) Time to adjudicated clinical worsening events. (B) Time to adjudicated clinical
worsening events by baseline risk stratification. “Lower risk” is defined as subjects with two or three
low-risk criteria met; “higher risk” is defined as subjects with zero or one low-risk criterion met.
*P values were calculated with log-rank test stratified by background pulmonary arterial hypertension
(PAH) therapy and baseline 6-minute-walk distance (6MWD) category. †Hazard ratios, 95%
confidence intervals (CIs), and P values were calculated with proportional hazard model with
explanatory variables of treatment, background PAH therapy, and baseline 6MWD as a continuous
variable.
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Safety
A total of 334 (96.5%) participants in the
oral treprostinil group and 219 (63.7%)
participants in the placebo group reported at
least one adverse event attributable to study
drug (Table 3). Headache, diarrhea,
flushing, nausea, and vomiting were more
commonly attributed to oral treprostinil
and were more often severe compared with
events attributed to placebo. Study drug
discontinuation because of adverse events
was substantially more common in oral
treprostinil–assigned participants (18.8%)
than in placebo participants (4.1%).
Discontinuation because of an adverse
event was more common before Week 24
(see Figure E6) and occurred at a median
(interquartile range) oral treprostinil dose
of 1.4 (0.4–3.0) mg three times daily.
Discussion
In the present study, oral treprostinil dosed
three times daily delayed a composite clinical
endpoint of time to first adjudicated clinical
worsening event by reducing the likelihood
of disease progression in participants, all
of whom were taking an approved oral
monotherapy for PAH. Hospitalizations and
deaths were balanced between groups as
components of the primary endpoint. This
study differs from previous sequential
combination studies (2, 3) in that
participants had a younger age, more recent
diagnosis, less severe symptoms, and better
baseline exercise capacity. Although
prostacyclin-class adverse events were
common and 18.8% of oral treprostinil
participants discontinued therapy because of
adverse events, active treatment facilitated
steady reductions in plasma NT-proBNP,
improved WHO functional class, and
reduced Borg dyspnea score after 6MWT, all
beginning at Week 12. Actual 6MWD was
improved at Weeks 36 and 48 in an analysis
that does not require imputation. Total daily
dose among actively treated participants at
Week 24 was 50% higher than that at Week
16 in the previous combination studies of
oral treprostinil (15, 16), and we postulate
that higher doses were possible, because
three times daily dosing reduced
peak–trough excursions in plasma
concentrations of treprostinil (6, 17).
Functional improvements, measured as
part of a multifaceted risk assessment, have
been repeatedly associated with improved
outcomes (12, 13, 18, 19). We prespecified
(before submission of the final statistical
analysis plan) use of the French risk
assessment, because we had collected the
three required noninvasive variables at
nearly all of the quarterly follow-up visits.
For those who remained on therapy,
participants taking oral treprostinil had a
favorable shift in this noninvasive risk at
Week 12, and the measured treatment
benefit in risk reduction persisted at Week
60. This shift reflected an improvement
in risk profile for 39% of oral treprostinil
participants at Week 60 and was
independent of the differences in the
primary event of clinical worsening (because
those participants had been censored). Our
data support the recently suggested “net
clinical benefit” strategy for clinical studies
of novel therapies in PAH (20).
The balanced appearance of baseline
characteristics in our study was deceiving
and revealed the need for a multifaceted
assessment of prognosis to ensure a reliable
assessment of subsequent treatment
efficacy. The unexpected imbalance in risk
profiles at baseline indicates that our
randomization strategy failed to create
comparable baseline groups. This may be
because the 350 m or lower breakpoint for
6MWD included less than 30% of the
baseline walks and/or because this 350-m
value is not a recognized transition point
for prognosis (21). The post hoc, risk-
adjusted analysis of the primary endpoint
demonstrating a greater treatment effect
indicates that future studies should
consider stratifying randomization based
upon background therapy and a validated
risk score to create cohorts that have a
similar prognosis at baseline (22). A failure
in this regard could lead to under- or
overestimation of the treatment effect.
Participants initially assigned placebo
had a similar rate of death at the end of
randomized treatment. A total of 108 of the
117 participants with an investigator-
reported, nonfatal clinical worsening event
in the primary study began therapy with oral
treprostinil in the extension study. An
apparent increase in survival for those
initially assigned oral treprostinil emerged
late in the study, but this observation must
be treated cautiously, because vital status
was unknown for 74 participants (11%). The
results still favored oral treprostinil,
assuming a proportional mortality among
those with unknown vital status (Tables E2
and E3). We know very little about
participants who discontinued the study.
Only vital status was collected via phone call;
we do not know the causes of death. Deaths
were distributed relatively uniformly
throughout the world with the exception of
India, which had a death rate of
approximately 20%. However, other
countries with less access to expensive,
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Figure 3. Plasma N-terminal pro–brain natriuretic peptide (NT-proBNP) results by study visit. Per
protocol, NT-proBNP values were not measured at Week 48. P value was obtained from the analysis
of covariance with change from baseline in log-transformed data in NT-proBNP as the dependent
variable, treatment as fixed effect, and log-transformed baseline NT-proBNP as a covariate. NT-
proBNP assay centrally performed by Covance via the Immulite 2000 on a Seimens platform. The
normal range for both sexes less than 75 years of age is less than 125 pg/ml. The normal range for
both sexes over 75 years of age is less than 450 pg/ml. IQR= interquartile range; LS= least squares;
PBO=placebo; TRE=oral treprostinil.
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approved PAH therapies (e.g., Mexico and
China) did not have excess deaths relative to
countries with more ready access. We know
nothing about treatment status for those
who died after discontinuing the study, and
treatment differences between the groups
might be an important confounder. Thus,
this apparent difference in mortality (using
the strategy prescribed in the final statistical
analysis plan) is intriguing, but must be
interpreted with appropriate context due to
the amount of missing data. In a recent
meta-analysis of 17 randomized, controlled
therapeutic trials in PAH, sequential therapy
was associated with a significant risk
reduction for clinical worsening (235%;
P, 0.001), but not mortality (214%;
P= 0.09) (23). Macitentan was associated
with a trend toward improved survival (2)
in a prespecified analysis, and initial
combination therapy improved survival (as
compared with initial monotherapy) in a
post hoc analysis (24). Although selexipag
prevented clinical worsening events overall
(3), death was numerically greater at the
end of randomized treatment and similar to
placebo through the end of the study.
Our study has important limitations.
Adverse effects typical for prostacyclin-class
medications were common, and the 18.8%
discontinuation rate was higher than for a
previous study of selexipag (14.3%).
It is conceivable that some of the oral
treprostinil–assigned participants who
stopped taking the drug because of adverse
events might have later had clinical
worsening, but we used standard censoring
methodology in generating the primary
outcome analysis. The protocol was
launched in 2013 when sequential
combination therapy was standard, but
initial combination therapy is becoming
increasingly common. It is unknown
whether the present results are
generalizable to patients in clinical practice
who are already taking two approved
therapies.
In conclusion, oral treprostinil
administered three times daily to a relatively
homogenous group of participants with
PAH who were taking oral monotherapy
reduced the likelihood of clinical worsening
due to disease progression. Plasma levels of
NT-proBNP dropped markedly with oral
treprostinil, and we also observed
improvements in investigator-assessed
WHO functional class and participant-
reported Borg dyspnea score after hallway
walking. Serial, noninvasive risk score
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Figure 4. Categorical changes from baseline in World Health Organization (WHO) functional class,
Borg dyspnea score, and risk stratification criteria. (A) WHO functional class categorical change from
baseline by study visit; participants who had a missing assessment at Week 24 and had deteriorated
were assigned functional class IV; P value was obtained from Fisher’s exact test. (B) Borg dyspnea
score categorical change from baseline by study visit; participants who had a missing assessment at
Week 24 and had deteriorated were assigned worst case of 10; P value was obtained from Fisher’s
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measurements appeared useful to
document treatment-related benefits, and a
prognostic score should be considered for
future outcome studies to balance baseline risk
profiles between the randomized treatment
groups. n
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Table 2. Primary and Secondary Efficacy Endpoints
Endpoint
Oral Treprostinil
(n=346)
Placebo
(n= 344) Treatment Effect (95% CI)
Primary endpoint: adjudicated clinical worsening
event, n (%)
All events 90 (26.0) 124 (36.0) HR, 0.74 (0.56 to 0.97); P=0.028*; P=0.039†
Death (all causes) 15 (4.3) 14 (4.1)
Hospitalization due to PAH and/or right heart
failure
35 (10.1) 35 (10.2)
Initiation of inhaled or infused prostacyclin 2 (0.6) 5 (1.5)
Disease progression 19 (5.5) 50 (14.5)
Unsatisfactory long-term clinical response 19 (5.5) 20 (5.8)
Secondary endpoints (at Week 24)
6MWD, LS mean change, m 16 8.03 7.96 (22 to 17.92); P=0.117‡
NT-proBNP, concentration ratio to baseline, LS
mean change
0.82 1.16 0.71 (0.61 to 0.82); P,0.001x
Borg dyspnea score, shift from baseline, n (%) P=0.014k
Improved 126 (36.5) 105 (30.5)
No change 128 (37.1) 113 (32.8)
Deteriorated 91 (26.4) 126 (36.6)
Combined ranking of 6MWD and Borg dyspnea
score
— — P=0.006¶
WHO functional class, shift from baseline, n (%) P=0.017k
Improved 51 (14.7) 37 (10.8)
No change 256 (74) 244 (70.9)
Deteriorated 39 (11.3) 63 (18.3)
Deaths (all causes), n (%)
Deaths during study 17 (4.9) 18 (5.2) HR, 1.00 (0.52 to 1.95); P=0.992*; P=0.978†
Deaths at closure of study** 38 (11.0) 60 (17.4) HR, 0.63 (0.42 to 0.95); P=0.026*; P=0.032†
Definition of abbreviations: 6MWD=6-minute-walk distance; CI = confidence interval; HR=hazard ratio; LS= least squares; MMRM=mixed-model
repeated measurement; NT-proBNP=N-terminal pro–brain natriuretic peptide; PAH=pulmonary arterial hypertension; WHO=World Health Organization.
*Hazard ratio, 95% CI, and P value were calculated with proportional hazard model with explanatory variables of treatment, background PAH therapy, and
baseline 6MWD as a continuous variable.
†
P value was obtained from log-rank test stratified by background PAH therapy and baseline 6MWD category.
‡LS mean, P value, estimated difference, and its 95% CI were from the MMRM with the change from baseline in 6MWD as the dependent variable,
treatment, week, treatment-by-week interaction, and background PAH therapy as the fixed effects, and baseline 6MWD as the covariate. An unstructured
variance/covariance structure shared across treatment groups was used to model the within-subject errors.
xLS mean, P value, estimated difference, and its 95% CI were from the MMRM with the change from baseline in log-transformed data in NT-proBNP as
the dependent variable, treatment, week, and treatment-by-week interaction as the fixed effects, and log-transformed baseline NT-proBNP as the
covariate. An unstructured variance/covariance structure shared across treatment groups was used to model the within-subject errors.
k
P value was obtained from Fisher’s exact test.
¶
P value obtained from nonparametric analysis of covariance.
**Vital status was collected at the study closure for all subjects including subjects who rolled over to extension study and who discontinued early from the
study. For subjects whose vital status was not available at the study closure, their time to death was censored at the subjects’ last known date to be alive.
Subjects who were alive at the study closure have their time to death censored at the last contact date.
Figure 4. (Continued). exact test. (C) Risk categorical change from baseline through Week 60. Percentages are calculated based on the number of
participants at each visit within each treatment group. Low-risk criteria are defined as WHO functional class I or II, 6-minute-walk distance .440 m,
or N-terminal pro–brain natriuretic peptide ,300 pg/ml. Low-risk criteria met were only counted for subjects with all three measures. “Improved” indicates
any increase in the number of low-risk criteria met; “no change” indicates the same number of low-risk criteria met; and “deteriorated” indicates any
decrease in the number of low-risk criteria met. P values were obtained from Fisher’s exact test. PBO=placebo; TRE=oral treprostinil.
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Table 3. Most Frequent Adverse Events
Variable
Oral Treprostinil (n=346)
[n (%)]
Placebo (n= 344)
[n (%)]
Any event reported 342 (98.8) 328 (95.3)
Any event probably or possibly related to
study drug
334 (96.5) 219 (63.7)
Study drug–related serious adverse
event
27 (7.8) 18 (5.2)
Study drug–related severe adverse event 78 (22.5) 27 (7.8)
Adverse events*
Headache 242 (69.9) 102 (29.7)
Diarrhea 227 (65.6) 68 (19.8)
Flushing 151 (43.6) 26 (7.6)
Nausea 128 (37.0) 58 (16.9)
Vomiting 111 (32.1) 26 (7.6)
Pain in jaw 60 (17.3) 8 (2.3)
Dizziness 52 (15.0) 45 (13.1)
Pain in extremity 48 (13.9) 11 (3.2)
Myalgia 44 (12.7) 23 (6.7)
*Adverse events listed are those probably or possibly related to study drug that occurred in more than
10% of participants in either study group.
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